C0243095||Nonamplification
C0242957||ERBB2
C0596611||genomic alterations
C0278493||recurrent
C0278488||metastatic breast cancer
C0243095||anti-HER2
C3854476||targeted therapies
C0243095||nonamplification
C0242957||ERBB2
C0596611||mutations
C0678941||ERBB2 mutations
C0021044||immunohistochemistry
C0021044||immunohistochemistry
C0162789||fluorescence in situ hybridization
C0162789||fluorescence in situ hybridization
C1294197||DNA sequencing
C4055223||clinical responses
C1702024||human epidermal growth factor receptor
C1702024||HER2
C3854476||targeted therapy
C0278488||advanced/metastatic breast cancers
C0278488||advanced/metastatic breast cancers
C0678941||ERBB2 mutations
C0596611||genomic alterations
C4055223||Clinical responses
C0243095||anti-HER2
C0087111||therapeutics
C0012854||DNA
C2711483||formalin-fixed paraffin-embedded (FFPE) sections
C0022885||Comprehensive genomic profiling
C0022885||Comprehensive genomic profiling
C0017337||genes
C1158746||base substitutions
C1956002||short indels
C2717926||copy number changes
C0017287||selected rearrangements
C0242957||ERBB2
C0596611||alterations
C0242957||ERBB2
C0017256||amplifications
C0017256||ERBB2 amplifications
C0678941||ERBB2 mutations
C0017256||ERBB2 amplifications
C0678941||ERBB2 mutations
C0678941||ERBB2 mutations
C0031727||kinase
C0521119||extracellular
C1517050||domains
C0678222||primary BC
C0005558||biopsies
C0678941||ERBB2 mutations
C0007097||carcinoma
C1134719||invasive ductal carcinoma
C1134719||invasive ductal carcinoma
C0279565||invasive lobular carcinoma
C0279565||invasive lobular carcinoma
C1334807||mucinous mBC
C0017337||Genes
C0242957||ERBB2
C0079419||tumor protein 53
C0079419||tumor protein 53
C1335212||phosphatidylinositol 3-kinase catalytic subunit alpha
C1335212||PIK3CA
C0694872||cadherin 1, type 1
C0694872||CDH1
C0086661||MYC
C1413172||cyclin D1 protein
C1413172||cyclin D1 protein
C0694872||CDH1
C0596611||mutations
C0678941||ERBB2 mutations
C0278488||advanced/metastatic breast cancers
C0678941||ERBB2 mutations
C0017256||ERBB2 amplifications
C0243095||anti-HER2
C3854476||targeted therapies
C0678941||ERBB2 mutations
C2936643||standard-of-care
C0021044||immunohistochemistry
C0162789||FISH tests
C0278488||Metastatic BC
C0678941||ERBB2 mutations
C0243095||anti-HER2
C3854476||targeted therapies
C0008976||clinical trials
C0678941||ERBB2 mutations
C0022885||Comprehensive genomic profiling
C3854476||targeted treatments